Brain Tumor Research

Richard Gilbertson136161-009

Below are highlights of recent Brain Tumor Program research.

Gene sequencing project identifies potential drug targets in common childhood brain tumor

St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project lifts lid on the most aggressive subtype of medulloblastoma and finds genes that cooperate in tumor development. (Dr. Richard Gilbertson)

Cancer sequencing initiative discovers mutations tied to aggressive childhood brain tumors

St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project provides first evidence linking cancer to mutations in genes involved in DNA organization. (Dr. Suzanne Baker)

Key regulatory genes often amplified in aggressive childhood tumor of the brainstem

Study led by St. Jude Children’s Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.

Key mutations act cooperatively to fuel aggressive brain tumor

St. Jude Children’s Research Hospital investigators use a novel model system to show how specific mutations can induce glioma formation in multiple regions of the brain and to begin studying patient response to a new generation of targeted therapies.

Different origins discovered for medulloblastoma tumor subtypes

International effort led by St. Jude Children’s Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers

St. Jude scientists develop new genomics-based approach to understand the origin of cancer subgroups

Scientists have long recognized that cancers may look the same under the microscope, but carry different mutations, respond differently to treatment and result in vastly different outcomes for patients.

Experimental targeted therapy shows early promise against medulloblastomas – a type of childhood brain cancer

Researchers from St. Jude Children’s Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented today at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor.

Push to understand basis of childhood brain tumors leads to a new treatment target

The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children’s Research Hospital clinical trial.

St. Jude Children’s Research Hospital and Washington University team to unravel genetic basis of childhood cancers

St. Jude Children’s Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world’s deadliest childhood cancers. The team has joined forces to decode the genomes of more than 600 childhood cancer patients who have contributed tumor samples for this historic effort.

St. Jude spotlights successes and challenges of childhood cancer

Advances in diagnosis and treatment mean more children are living longer with cancer than ever before, with about 270,000 childhood cancer survivors alive today nationwide. Despite these advances, cancer remains the leading cause of death due to disease among U.S. children over one year of age.

Study shows how defective DNA repair triggers two neurological diseases (news release)

St. Jude scientists’ findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases.